<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>477-SPIRONOLACTONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SPIRONOLACTONE" rxcui="9997">
<ATC code="C03DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>With the spironolactone in dosages from 12.5 to 50 mg per day, and with weak doses of the ACE inhibitor.

In the treatment of class III or IV heart failure (NYHA) with an ejection fraction &lt;35% and previous treatment with an ACE inhibitor + a loop diuretic: risk of hyperkalemia, potentially lethal, in case of failure to follow the prescription conditions for this combination of medications. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>477-SPIRONOLACTONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SPIRONOLACTONE" rxcui="9997">
<ATC code="C03DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MITOTANE" rxcui="7004">
<ATC code="L01XX23" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of blocking of the action of the mitotane by the spironolactone</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
